Research programme: immuno-microbials - Evelo Biosciences

Drug Profile

Research programme: immuno-microbials - Evelo Biosciences

Alternative Names: EDP 1815; Immuno-microbial therapeutics - Evelo Biosciences; Monoclonal microbial therapeutics - Evelo Biosciences

Latest Information Update: 29 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Epiva Biosciences
  • Developer Evelo Biosciences
  • Class Antipsoriatics; Antirheumatics; Bacteria; Immunotherapies; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Atopic dermatitis; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 29 May 2018 Preclinical trials in Atopic dermatitis in USA (PO) (Evelo Biosciences pipeline, May 2018)
  • 29 May 2018 Preclinical trials in Psoriasis in USA (PO) (Evelo Biosciences pipeline, May 2018)
  • 29 May 2018 Preclinical trials in Rheumatoid arthritis in USA (PO) (Evelo Biosciences pipeline, May 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top